| answer text |
<p>It is a key commitment of this Government to ensure that people with comparatively
rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy
in medicines as those who have more common conditions.</p><p> </p><p>However, it is
also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must
go through the right process with Vertex and NHS England, not the Government, working
together to secure the best outcome for patients. NHS England has been in intensive
discussions with Vertex to encourage it to price Orkambi at a level that would allow
NHS England to fund its use without adversely impacting other patients. I and the
Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping
an extremely close eye on these discussions and wrote to Vertex in April, urging it
to commit to pricing that is responsible and proportionate. I also re-iterated this
message in the adjournment debate on 17 July, Official report, columns 383-4.</p>
|
|
